Arrow Therapeutics focuses on anti-infective therapeutics. The company develops compounds for treating respiratory syncytial virus (RSV), hepatitis C virus (HCV) and herpes virus (HV) and is pursuing a significant antibacterial program. Arrow has two ongoing programs for HCV as well as a program to treat HV at the lead optimization stage. Arrow as developed an antibiotic drug discovery approach, Transposon Mediated Differential Hybridization (TMDH) that identifies each essential gene in a microbial genome using proprietary in situ synthesis DNA microarrays. TMDH technology identifies attenuating genes for potential vaccine candidates.